This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Lee, S. M. et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet https://doi.org/10.1016/S0140-6736(23)00774-2 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. Platinum-ineligible: atezolizumab preferable. Nat Rev Clin Oncol 20, 661 (2023). https://doi.org/10.1038/s41571-023-00806-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00806-6